Overview

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa

Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
TWi Biotechnology, Inc.